Senaparib

塞纳帕利

Report date: 2026/04/08 15:32:16
NME

Base Information

Drug NameSenaparib
Drug Alias Name派舒宁IMP-4297IMP-04297JS-109
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1Poly (ADP-Ribose) Polymerase 2
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[10] 
Global Approved IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial
Approved Indications in ChinaFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial
Original Approved Country/TerritoryMainland China
Original Approved Date2025/01/14
Country/TerritoryUnited StatesTaiwanAustralia +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesImpact Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesImpact Therapeutics IncShanghai Yingpai Pharmaceutical Co LtdShanghai Impact Pharmaceutical Co Ltd
Inactive CompaniesShanghai Junshi Biosciences Co LtdWuxi Sta Pharmaceutical Co Ltd
Active IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank